Editas Medicine

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.

We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Stock Symbol: EDIT

Stock Exchange: NASDAQ

11 Hurley Street
Cambridge, Massachusetts 02141 USA
AWARDS
  • NextGen Class of 2015
NEWS
The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to Broad, not UC Berkeley.
Three genome editing companies, Intellia Therapeutics, Editas Medicine and uniQure, are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.
ProQR Therapeutics has reported that their drug sepofarsen failed to meet its primary and secondary endpoints in recent Phase II/III clinical trials.
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
It was yet another busy week for clinical trial news. Here’s a look.
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
JOBS
IN THE PRESS